This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide

Ticker(s): ZEAL, NVO, LLY

Who's the expert?

Institution: NYU Langone Health

  • Clinical Assistant Professor of Medicine at NYU Grossman School of Medicine 
  • Manages over 300 patients a month with type 2 diabetes and obesity
  • Research interest in weight loss maintenance and obesity medicine

Interview Questions
Q1.

Roughly how many patients with obesity do you manage?

Added By: ben_admin
Q2.

On a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for Petrelintide?

Added By: ben_admin
Q3.

What is your high level view on the potential of long-acting amylin analogs for weight management?

Added By: ben_admin
Q4.

Are you convinced that long-acting amylin analogs are more efficaious and/or safer than GLP-1 medications?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.